Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:55 PM ET in New York, NY.
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:55 PM ET in New York, NY.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. www.millendo.com
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. www.millendo.com
Source: Millendo Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180315005217/en
